Upstream Bio represents a high-risk, high-reward proposition typical of clinical-stage biotechnology developers, where future investment returns depend almost entirely on successful drug trial outcomes and regulatory milestones rather than current product sales. What is your specific investment horizon, and how do you manage volatility in your portfolio?